Resverlogix Corp. (TSE:RVX – Get Free Report)’s share price reached a new 52-week low on Friday . The stock traded as low as C$0.05 and last traded at C$0.05, with a volume of 216634 shares changing hands. The stock had previously closed at C$0.05.
Resverlogix Price Performance
The company has a quick ratio of 0.04, a current ratio of 0.13 and a debt-to-equity ratio of -10.95. The company has a market cap of C$8.91 million, a price-to-earnings ratio of -2.23 and a beta of 0.71. The company has a fifty day simple moving average of C$0.05 and a two-hundred day simple moving average of C$0.06.
Resverlogix Company Profile
Resverlogix Corp clinical-stage biotechnology company. The company is developing an advanced epigenetic drug called apabetalone for the treatment of patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, peripheral artery disease, orphan diseases, and neurodegenerative diseases.
Read More
- Five stocks we like better than Resverlogix
- How to Most Effectively Use the MarketBeat Earnings Screener
- Why Genuine Parts Company Is a Royally Good Buy Right Now
- 3 Small Caps With Big Return Potential
- Industrials Are Quietly Outpacing the Market: 3 Stocks to Watch
- P/E Ratio Calculation: How to Assess Stocks
- These 5 Energy Stocks Hedge Inflation With Growth Potential
Receive News & Ratings for Resverlogix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Resverlogix and related companies with MarketBeat.com's FREE daily email newsletter.
